# US 8,278,269 B2 · Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,269 B2
- Document ID: US8278269B2
- Status: Granted
- Kind: B2
- Application number: 10/473,571
- Filed: 2002-03-29
- Published: 2005-03-10
- Granted: 2012-10-02
- Earliest claimed: 2001-03-29
- Assignees: The University of Chicago
- Inventors: Terence Martin; F. Gary Toback; Margaret Walsh-Reitz
- Web page: https://patentgrep.com/patent/US8278269B2

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/475: Growth factors; Growth regulators
- A01K 2217/075: inducing loss of function, i.e. knock out
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA, cDNA and the AMP-18 protein are sequenced for human, mouse and pig. The AMP-18 protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides capable of inhibiting the effects of the complete protein, are also derived from the AMP-18 protein. Cytoprotection and control of mammalian gastro-intestinal tissue growth and repair (restitution) is facilitated by the use of the proteins, making the proteins candidates for therapies in inflammatory bowel disease and gastric ulcers.

## Claims

### Claim 1

A pharmaceutical composition comprising a therapeutically effective amount of a growth promoting peptide comprising the mitogenic amino acid sequence, VKE(K/Q)KLQGKGPGG(P/A)PPK (SEQ ID NO: 25) wherein there is a Q at position 4 and a P at position 14.

### Claim 2

A pharmaceutical composition comprising a therapeutically effective amount of a growth promoting peptide consisting of a mitogenic amino acid sequence, selected from the group consisting of KKLQGKGPGGPPPK (SEQ ID NO: 11), LDALVKEKKLQGKGPGGPPPK (SEQ ID NO: 12), and LDALVKEKKLQGKGPGGPPPKGLMY (SEQ ID NO: 13).

### Claim 3

A pharmaceutical composition comprising a therapeutically effective amount of a growth promoting peptide comprising the mitogenic amino acid sequence VKE(K/Q)KGKGPGG(P/A)PPK (SEQ ID NO: 26).

### Claim 4

A pharmaceutical composition comprising a therapeutically effective amount of a growth promoting peptide consisting of the mitogenic amino acid sequence KKTCIVHKMKKEVMPSIQSLDALVKEKKLQGKGPGGPPPKGL (SEQ ID NO:17).

### Claim 5

A pharmaceutical composition comprising a therapeutically effective amount of a growth promoting peptide comprising the mitogenic amino acid sequence VKE(K/Q)KLQGKGPGG(P/A)PPK (SEQ ID NO: 25) wherein there is a Q at position 4 and an A at position 14.

### Claim 6

A pharmaceutical composition comprising a therapeutically effective amount of a growth promoting peptide comprising the mitogenic amino acid sequence VKE(K/Q)KLQGKGPGG(P/A)PPK (SEQ ID NO: 25) wherein there is a K at position 4 and an A at position 14.
